XBiotech Inc
xbiotech.comWhat Do They Do?
Develops human-derived antibody therapies for treating inflammatory and infectious diseases, including cancer, stroke and infections.
10-K for FY2025, filed Mar 13, 2026XBiotech Inc. (“XBiotech” or the “Company”) is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies…View ↗
XBiotech’s True Human™ monoclonal antibodies are derived from human donors that mount a natural human immune response. All other marketed…View ↗
While market potential keeps XBiotech focused on anti-IL-1a therapies, unmet medical need and the potential for uniquely effective product…View ↗
The Company currently has a clinical stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical…View ↗
Who Are Their Customers?
A pharmaceutical company bought drug manufacturing and clinical-trial services under supply and service agreements; those agreements ended by the end of 2023.
10-K for FY2025, filed Mar 13, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$6.7MView ↗
- ▲ +283% (Loss)
- vs −$1.8M in Q2 FY2025
Contract services ended
The earlier report described drug manufacturing and clinical-trial services under supply agreements; the latest says those agreements concluded and XBiotech no longer provides either service under them.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 13, 2026Since January 1, 2020 XBiotech also used its proprietary manufacturing technology, its manufacturing plant and infrastructure to produce…View ↗
Starting in 2020, XBiotech used its proprietary manufacturing technology, its manufacturing plant and infrastructure to produce drug…View ↗
Stroke study put on hold
The earlier report said XBiotech had filed an investigational application for a stroke treatment; the latest says its planned stroke study is on hold pending clarity on cancer and arthritis regulatory paths.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 13, 2026IL-1a plays a key role in many disease processes. While it is produced naturally by the body, when not properly controlled, in situations…View ↗
XBiotech filed an investigational new drug application in 2022 for our True Human™ antibody Hutrukin. Hutrukin is a candidate therapeutic…View ↗
Rheumatology results became uninterpretable
The earlier report described a rheumatology clinical program; the latest says site irregularities made its study data uninterpretable, though XBiotech continues to see potential in the treatment.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 13, 2026IL-1a plays a key role in many disease processes. While it is produced naturally by the body, when not properly controlled, in situations…View ↗
The Company launched a clinical Rheumatology program in August, 2023. A total of 233 subjects were enrolled into a double blind…View ↗
Loading...
